Acquired hemophilia
ICD-10 D68.311 is a billable code used to indicate a diagnosis of acquired hemophilia.
Acquired hemophilia is a rare bleeding disorder characterized by the development of autoantibodies against clotting factor VIII, leading to a deficiency in its activity. Unlike congenital hemophilia, which is inherited, acquired hemophilia typically arises in adults and can be associated with various underlying conditions, including autoimmune diseases, malignancies, and certain medications. Patients with acquired hemophilia often present with spontaneous bleeding, particularly in soft tissues, muscles, and joints, which can be life-threatening. Diagnosis is confirmed through laboratory tests that reveal prolonged activated partial thromboplastin time (aPTT) and the presence of inhibitors against factor VIII. Management involves the use of bypassing agents, such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa, and immunosuppressive therapy to eradicate the inhibitors. The condition requires careful monitoring and a multidisciplinary approach to treatment, particularly in patients with concurrent bleeding disorders or those on anticoagulation therapy.
Detailed lab results, treatment plans, and patient history.
Patients presenting with unexplained bleeding, those with known autoimmune disorders, and patients undergoing treatment for malignancies.
Documentation must clearly indicate the acquired nature of the hemophilia and any associated conditions.
Comprehensive patient history, medication lists, and any relevant imaging or lab tests.
Patients with unexplained bruising or bleeding, particularly in older adults or those with chronic illnesses.
Attention to detail in documenting the patient's overall health and any potential drug interactions.
Used to confirm the diagnosis of acquired hemophilia.
Lab results must be documented in the patient's medical record.
Hematology specialists should ensure accurate interpretation of results.
Acquired hemophilia is primarily caused by the development of autoantibodies against factor VIII, often triggered by underlying conditions such as autoimmune diseases or malignancies.
